From the Yahoo Tetra Board - copied for your reading pleasurFrom Yahoo Tetra message board: Tetra is the only pharmaceutical company doing smoked cannabis and oils in clinical trials with FDA Health Canada. The market JUST IN CANADA is $3.2 BILLION annually spent just by PATIENTS taking MMJ. Don't even try to calculate in the USA. Wow. Over 400,000 MMJ patients registered in Canada right now. Average spend by each is $8,000 a year. Most pay with their own cash. Read on about when Tetra obtains its DIN number for PPP001 and the indications are widened to use it for other conditions and they transition it to oil. Hence, this is what they are doing, expanding the scope of PPP001. Samuel4 days ago I knew TBP would bounce back quick. These guys will be in the $1.5-2 range by the end of 2019 ReplyReplies (1)141 Gee Gee19 minutes ago But didn't they say, besides all the new revenue generating products they are rolling out, they are going to be bringing PPP001 to market in 2019. The DIN# is only delayed by at most six months from the news release. They also have other money makers going on. If they do obtain the DIN#, the price will not be anywhere near $1.50-2.00. Consider this from the Health Europa article on Tetra Biopharma released 2-12-19: The article brings this out about the actual opportunity that Tetra Bio-Pharma has with the pathway to success they have chosen, being one of only two "cannabis" companies working with both Health Canada and FDA regulators via the pharmaceutical pathway. So what is the opportunity? "Until and unless cannabinoid-derived pharmaceuticals can meet the stringent standards for drug approval, access to cannabinoid-derived medicines will not find their way into the mainstream medical system and not likely be covered by health insurance. In Canada, as an example, patients pay between $4,000 (~€2,647) and $12,000 annually for medical cannabis – a cost that could be significantly reduced once cannabinoid-derived medicines are approved." "... When cannabinoid products are approved as drugs, they will be available in pharmacies, ensuring both quality and controlled dosing. Reimbursement by private or public health plans for approved cannabinoid medications will represent a significant benefit to patients not only in terms of confidence and convenience but by the elimination of the stigma associated with cannabis." "... The promise of cannabis as an alternative to opioids such as fentanyl is compelling at a societal level as the opioid epidemic continues to rise, affecting millions across North America. From a patient care perspective, clinical data indicates that cannabinoid-based drugs can provide rapid relief in patients suffering from breakthrough pain in contrast to fentanyl’s slower mechanism of action." So the energy drink, Hemp Energy Drink is doing well. That's enough if that's all they did, if you see that keep rolling out in Canada and USA. Coast to coast sales? All NA? Then add on top of that DIN approval and patients accessing PPP001 (under its new name) via their insurance. I will venture that the price patients are currently paying for non-FDA approved, non-insured medical cannabis will be at least what the insurance companies will hope to pay for Tetra's PPP001. But since it has been so well researched and successfully proven, by the rigorous regulatory pathway, you should expect the price for PPP001 will be more than what people are paying out of pocket for their favorite medical cannabis. They said from $4,000 to $12,000 a year (€2,647 to €7,941) is what they are paying now, so you simply have to expect patients' approved cannabis from Tetra will be at least that much. AT LEAST. But go ahead and analyze just those figures. $4K to 12K Canadian dollars. How many patients will make the move? ========================== Question: How many patients will make the move over to insurance-covered medical cannabis? Answer: ALL OF THEM THAT POSSIBLY CAN. Don't think so? You should KNOW so! If you think for one minute that anybody now paying out of pocket $4,000 - $12,000 CAD is going to keep doing that (buying it with their own money, although most of them can barely afford to do so), when they can put that money into their piggy banks instead and go to their doctors and have their health insurance cover it? That is absolutely what is going to happen. And the insurance companies will gladly do so because they know this will eliminate much opioid use as well. Then add to that the fact that even in Canada there is resistance from doctors to recommend cannabis to patients since all the cannabis hasn't been through clinical testing, and so you have to add the whole group of new doctors who will be prescribing PPP001 because they have the research to back it up. So if 20,000 doctors right now recommended cannabis to patients (they can't prescribe "" a drug if it has no DIN number), once PPP001 is approved for sale, you will see an immediate jump in the number of doctors who write the order for it for their patients. There were 201,000 MMJ registered patients in Canada in Q2 2017. From the graph, I would guesstimate the number is now over 400,000. (201K + 6x30K = 389,000 and consider that the amount each quarter has grown the 10 quarters through Q2 2017 in each quarter like this: Q2 2015 5,000 new patients, Q3 2015 7,000 new patients, Q4 2015 9,000 new patients; permit me some shorthand: Q116 +14,000; Q216 +21,500; Q316 +23,000; Q416 +31,500; Q117 +38,000; Q217 +33,500. It's now a year and a half past Q2 2017, and I would expect current addtions to be over 40,000 new patients added quarterly. That is expected to increase overall due to all the progress in many things the last few years. The chart predicts continued growth in quarterly additions to MMJ patient roles. ========================== Less Reply1 Gee Gee2 seconds ago @Samuel This second chart adds another 4 quarters to my projection above. It puts the tally at Q2 2018 at 330,700 registered Canadian patients. Turns out that these 4 quarterly increases were up +34,000 three times and up +27,000 one time. It's short two quarters of data, so if we take the weighted average of those four to calculate/guesstimate the last two quarters now shown here, it's about +32,5000 a quarter average. That gives 395,700 registered patients at this time. For simple math, let's call it 400,000 registered MMJ patients in Canada. We know they spend from $4,000 to $12,000 CAD annually on MMJ. Take the simple average of this range to get an approximate average per person: ($4,000 + $12,000) / 2 = $8,000 per person, assuming a normal bell curve of distribution. Next total all that cash: 400,000 patients ($8,000 annual expenses) = how much? Do you guess it's millions, tens of millions, hundreds of millions, or billions? ~ $8,000 x 4,000 patients is $32 million purchased. ~ $8,000 x 40,000 patients is $320 million purchased ~ $8,000 x 400,000 patients is $3.2 BILLION purchased. Most of them you would think would want their insurance to cover that. Most of these do not represent but a small minority of doctors who are willing to recommend it, so multiply by some factor for the big increase in doctors prescribing PPP001. https://www.statista.com/statistics/603356/canadian-medical-marijuana-clients-registered-by-quarter/